We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The premarket approval allows the labeling to state that clinical data showed statistical superiority over autologous bone graft was maintained in its second-year follow-up. Read More